Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $170 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Li Watsek has reiterated an Overweight rating on Ascendis Pharma (NASDAQ:ASND) and maintained a price target of $170.
September 09, 2024 | 3:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Ascendis Pharma, maintaining a price target of $170. This suggests confidence in the company's future performance.
The reiteration of an Overweight rating and a high price target by a reputable analyst suggests positive sentiment and potential upside for Ascendis Pharma's stock. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100